Please assess the completion status of the following clinical trial:

Trial Title: Prospective Clinical Study of the Guidant Microwave Ablation System for the Treatment of PAF in the MIS Procedure

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patient is greater than or = 18 years of age~* Patient has documented symptomatic paroxysmal atrial fibrillation (PAF) refractory to at least 1 antiarrhythmic (Class IA, IC, III) drug.~* Patient has episodes of symptomatic AF including, but not limited to, palpitations, lightheadedness, fatigue, dyspnea, and/or chest pain.~* A minimum of a 6-month history of symptomatic paroxysmal AF (documented by patient report in the medical record).~* A minimum of 2 discrete symptomatic paroxysmal AF episodes in the month prior to study entry. Paroxysmal AF rhythm must be documented by objective evidence (12-lead electrocardiogram \[ECG\], Holter monitor, event monitor, or other telemetry rhythm strip) with the presence of sinus rhythm and/or underlying rhythm between episodes.~* Patient has been informed of the nature of the study, agreed to its provisions, and provided written informed consent.~Exclusion Criteria:~* Patient had a cerebral vascular accident or transient ischemic attack within the previous 6 months.~* Patient had a myocardial infarction within the previous 6 weeks.~* Patient has underlying metabolic etiology related to AF (e.g., hyperthyroidism, metabolic disorder).~* Patient has significant underlying structural heart disease (e.g., valvular disease, presence of aneurysm, left ventricular hypertrophy) requiring surgical or procedural intervention.~* Patient with prior catheter ablation procedure for the treatment of AF within the previous 6 months.~* Patient has evidence of, or history of, 50% or more stenosis in any pulmonary vein.~* Patient had a previous thoracic procedure resulting in sternal opening and/or pericardial opening (e.g., surgical ablation, coronary artery bypass graft \[CABG\], or valve repair).~* Patient has a left atrial size \> 6.0 cm measured on echocardiogram.~* Patient has a left ventricular ejection fraction (LVEF) \< 35%.~* Patient requires treatment for CAD (coronary artery disease) or has untreated unstable angina.~* Patient has a presence of esophageal fistula or esophageal stricture, untreated esophagitis, varices, dysphagia, or odynophagia caused by anatomical abnormality or other diseases contraindicating transesophageal echocardiography.~* Patient has severe chronic obstructive pulmonary disease.~* Patient has a known allergy or contraindication to Coumadin (warfarin) therapy, or inability to comply with Coumadin (warfarin) therapy.~* Patient has a known allergy or contraindication to complying with antiarrhythmic (Class IA, IC, III) therapy.~* Patient has an acute illness or active systemic infection or sepsis.~* Patient has a co-morbidity with life expectancy of less than one year or protocol non-compliance that would limit follow-up.~* Patient is geographically remote and/or unable to return for follow-up examinations.~* Patient is pregnant or is planning to become pregnant during the study.~* Patient is enrolled in any concurrent study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: None

Based on this trial design, predict the completion outcome and termination type (if applicable).